title: Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-Helicobacter pylori therapy.
abstract: The most common primary lymphoma of the gastrointestinal tract is B-cell lymphoma arising from mucosa-associated lymphoid tissue known as MALT lymphoma. Although the majority of these lesions affect the stomach and are associated with Helicobacter pylori organisms, sites other than the gastrointestinal tract may be affected. This case report describes a patient with concomitant laryngeal MALT lymphoma and Helicobacter pylori-related gastric MALT lymphoma derived from the same clone as confirmed by PCR. Treatment of Helicobacter pylori infection in this patient using antibiotics led to regression of both lesions. This patient remains in remission at 46-month follow-up. This is the first case report on the regression of a laryngeal MALT lymphoma after Helicobacter pylori eradication. We suggest that all patients presenting with extragastric MALT lymphoma should undergo upper gastrointestinal endoscopy with gastric biopsies for the determination of Helicobacter pylori status and presence of concomitant gastric MALT lymphoma, followed by a course of anti-Helicobacter pylori antibiotic therapy. Nonresponders may subsequently be considered for surgery and/or chemo/radiation therapy.
authors.affiliation: Department of Internal Medicine and Gastroenterology, University of Bologna, Italy. g.caletti@ausl.imola.bo.it
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Caletti
authors.forename: Thomas
authors.initials: T
authors.lastname: Togliani
authors.forename: Pietro
authors.initials: P
authors.lastname: Fusaroli
authors.forename: Elena
authors.initials: E
authors.lastname: Sabattini
authors.forename: Edna
authors.initials: E
authors.lastname: Khodadadian
authors.forename: Barbara
authors.initials: B
authors.lastname: Gamberi
authors.forename: Marco
authors.initials: M
authors.lastname: Gobbi
authors.forename: Stefano
authors.initials: S
authors.lastname: Pileri
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007822:Laryngeal Neoplasms / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents